Washington: People who receive COVID-19 vaccines by Pfizer and Moderna are up to 91 per cent less likely to develop the disease, according to a US study which also suggests that the preventives reduce the severity of symptoms and duration in those who still get an infection.
The research, published in the New England Journal of Medicine on June 30, is among the first to show the benefits of mRNA vaccines even among those who experience breakthrough infections -- testing positive after immunisation.
The mRNA vaccines by Pfizer and Moderna contain genetic instructions for our cells to make the spike protein of the SARS-CoV-2, which the virus uses to infect and enter the human cells.